Final progression-free survival analysis of BOLERO-2: a phase Ill trial of everolimus for postmenopausal women with advanced breast cancer

被引：3
|
作者：
Piccart, M.
Baselga, J.
Noguchi, S.
Burris, H.
Gnant, M.
Hortobagyi, G.
Mukhopadhyay, P.
Taran, T.
Sahmoud, T.
Rugo, H.
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Osaka Univ, Osaka, Japan
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-126-04-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-04-02
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
    Vakaramoko Diaby
    Georges Adunlin
    Askal Ayalew Ali
    Rima Tawk
    Breast Cancer Research and Treatment, 2014, 146 : 669 - 673
  • [32] Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial
    Baselga, J.
    Campone, M.
    Piccart-Gebhart, M. J.
    Burris, H. A.
    Rugo, H. S.
    Noguchi, S.
    Gnant, M.
    Pritchard, K. I.
    Lebrun, F.
    Beck, J. T.
    Ito, Y.
    Yardley, D. A.
    Deleu, I.
    Perez, A.
    Bachelot, T. D.
    Vittori, L.
    Mukhopadhyay, P.
    Weber, D.
    Sahmoud, T.
    Hortobagyi, G. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] SAFETY OF EVEROLIMUS FOR WOMEN OVER 65 YEARS OF AGE WITH ADVANCED BREAST CANCER: 18-MO FOLLOW-UP OF BOLERO-2
    Gnant, M.
    Noguchi, S.
    Ito, Y.
    Piccart, M.
    Baselga, J.
    Panneerselvam, A.
    Taran, T.
    Sahmoud, T.
    Hortobagyi, G. N.
    Pritchard, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 126 - 127
  • [34] Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial
    Hrebien, S.
    Citi, V
    Garcia-Murillas, I
    Cutts, R.
    Fenwick, K.
    Kozarewa, I
    McEwen, R.
    Ratnayake, J.
    Maudsley, R.
    Carr, T. H.
    de Bruin, E. C.
    Schiavon, G.
    Oliyeira, M.
    Turner, N.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 945 - 952
  • [35] IN ADVANCED/METASTATIC BREAST CANCER, IS PROGRESSION-FREE SURVIVAL A SURROGATE OUTCOME?
    Franca, A. C.
    Schroeder, L.
    Padilla, M.
    Meirelles, I
    Silva, A. S.
    Magliano, C.
    Santos, M.
    VALUE IN HEALTH, 2020, 23 : S477 - S478
  • [36] Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2
    Prat, Aleix
    Christoph Brase, Jan
    Cheng, Yuan
    Nuciforo, Paolo
    Pare, Laia
    Pascual, Tomas
    Martinez, Debora
    Galvan, Patricia
    Vidal, Maria
    Adamo, Barbara
    Hortobagyi, Gabriel N.
    Baselga, Jose
    Ciruelos, Eva
    ONCOLOGIST, 2019, 24 (07): : 893 - 900
  • [37] Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
    J. Thaddeus Beck
    Gabriel N. Hortobagyi
    Mario Campone
    Fabienne Lebrun
    Ines Deleu
    Hope S. Rugo
    Barbara Pistilli
    Norikazu Masuda
    Lowell Hart
    Bohuslav Melichar
    Shaker Dakhil
    Matthias Geberth
    Martina Nunzi
    Daniel Y. C. Heng
    Thomas Brechenmacher
    Mona El-Hashimy
    Shyanne Douma
    Francois Ringeisen
    Martine Piccart
    Breast Cancer Research and Treatment, 2014, 143 : 459 - 467
  • [38] Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
    Beck, J. Thaddeus
    Hortobagyi, Gabriel N.
    Campone, Mario
    Lebrun, Fabienne
    Deleu, Ines
    Rugo, Hope S.
    Pistilli, Barbara
    Masuda, Norikazu
    Hart, Lowell
    Melichar, Bohuslav
    Dakhil, Shaker
    Geberth, Matthias
    Nunzi, Martina
    Heng, Daniel Y. C.
    Brechenmacher, Thomas
    El-Hashimy, Mona
    Douma, Shyanne
    Ringeisen, Francois
    Piccart, Martine
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 459 - 467
  • [39] A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2- advanced breast cancer
    Jerusalem, Guy
    Bachelot, Thomas
    Barrios, Carlos
    Neven, Patrick
    Di Leo, Angelo
    Janni, Wolfgang
    de Boer, Richard
    CANCER TREATMENT REVIEWS, 2015, 41 (02) : 94 - 104
  • [40] Progression-free survival results in postmenopausal Asian women: Subgroup analysis from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)
    Shao, Z.
    Ellis, M. J.
    Robertson, J. F. R.
    Grinsted, L. M.
    Fazal, M.
    Noguchi, S.
    CANCER RESEARCH, 2017, 77
12345